NCCN has the following processes in place to ensure transparency of the NCCN Guidelines update process.
Acute Lymphoblastic Leukemia Panel
Version: 3.2024 ( Acute Lymphoblastic Leukemia )
Date: 2024-11-04 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2024-01-08 Transparency Panel Disclosures/Attendance
Date: 2023-11-08 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Acute Lymphoblastic Leukemia )
Date: 2023-10-03 Transparency Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-06-21 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2023-04-27 Transparency Panel Disclosures/Attendance
Date: 2022-11-02 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-19 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-11-19 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-07-13 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-02-10 Transparency Panel Disclosures/Attendance
Date: 2020-11-06 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-07-25 Transparency Panel Disclosures/Attendance
Date: 2023-05-02 Transparency Panel Disclosures/Attendance
Version: 5.2023 ( Acute Myeloid Leukemia )
Date: 2023-07-26 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-04-08 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Acute Myeloid Leukemia )
Date: 2022-04-08 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Acute Myeloid Leukemia )
Date: 2021-11-02 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Acute Myeloid Leukemia )
Date: 2021-11-02 Transparency Panel Disclosures/Attendance
Date: 2021-10-18 Transparency Panel Disclosures/Attendance
Date: 2021-05-13 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-30 Transparency Panel Disclosures/Attendance
Date: 2020-05-26 Transparency Panel Disclosures/Attendance
Date: 2020-05-19 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-09-16 Transparency Panel Disclosures/Attendance
Adolescent and Young Adult Oncology Panel
Version: 3.2023
Date: 2022-12-20 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Adult Cancer Pain )
Date: 2024-03-06 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Adult Cancer Pain )
Date: 2023-09-28 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Adult Cancer Pain )
Date: 2022-09-12 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-03 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Antiemesis )
Date: 2023-09-18 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Antiemesis )
Date: 2021-09-24 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-17 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( B-Cell Lymphomas )
Date: 2024-09-11 Transparency Panel Disclosures/Attendance
Date: 2024-09-10 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Castleman Disease )
Date: 2024-11-13 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( B-Cell Lymphomas )
Date: 2024-04-10 Transparency Panel Disclosures/Attendance
Date: 2024-03-08 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-12-01 Transparency Panel Disclosures/Attendance
Date: 2023-09-29 Transparency Panel Disclosures/Attendance
Version: 6.2023
Date: 2023-10-03 Transparency Panel Disclosures/Attendance
Version: 5.2023
Date: 2023-06-29 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( B-Cell Lymphomas )
Date: 2023-05-25 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( B-Cell Lymphomas )
Date: 2023-04-26 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( B-Cell Lymphomas )
Date: 2023-02-01 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( B-Cell Lymphomas )
Date: 2022-09-21 Transparency Panel Disclosures/Attendance
Date: 2022-09-20 Transparency Panel Disclosures/Attendance
Version: 5.2022
Date: 2022-06-30 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( B-Cell Lymphomas )
Date: 2022-06-01 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( B-Cell Lymphomas )
Date: 2022-01-21 Transparency Panel Disclosures/Attendance
Date: 2021-12-06 Transparency Panel Disclosures/Attendance
Date: 2021-09-28 Transparency Panel Disclosures/Attendance
Version: 5.2021 ( B-Cell Lymphomas )
Date: 2021-09-15 Transparency Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-04-28 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-10 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-09 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-22 Transparency Panel Disclosures/Attendance
Date: 2020-09-22 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-08-04 Transparency Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-07-28 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-06-23 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Penile Cancer )
Date: 2024-08-13 Transparency Panel Disclosures/Attendance
Version: 5.2024 ( Bladder Cancer )
Date: 2024-10-23 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Bladder )
Date: 2024-04-24 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-03-11 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Bladder )
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Bladder )
Date: 2022-08-26 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Bladder Cancer )
Date: 2022-08-26 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Bladder Cancer )
Date: 2022-08-26 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Bladder Cancer )
Date: 2022-12-21 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Bladder Cancer )
Date: 2021-09-24 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Penile Cancer )
Date: 2021-09-24 Transparency Panel Disclosures/Attendance
Version: 5.2021 ( Bladder Cancer )
Date: 2021-10-12 Transparency Panel Disclosures/Attendance
Date: 2021-10-12 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Bladder Cancer )
Date: 2021-07-13 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Bladder Cancer )
Date: 2021-06-28 Transparency Panel Disclosures/Attendance
Date: 2021-04-14 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Bladder Cancer )
Date: 2021-03-11 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Bladder Cancer )
Date: 2021-02-22 Transparency Panel Disclosures/Attendance
Date: 2020-09-29 Transparency Panel Disclosures/Attendance
Date: 2020-09-18 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Penile Cancer )
Date: 2020-09-29 Transparency Panel Disclosures/Attendance
Version: 6.2020 ( Bladder Cancer )
Date: 2020-07-02 Transparency Panel Disclosures/Attendance
Version: 4.2020 ( Bladder Cancer )
Date: 2020-04-21 Transparency Panel Disclosures/Attendance
Version: 3.2020 ( Bladder Cancer )
Date: 2020-01-14 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Bone Cancer )
Date: 2024-05-23 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Bone Cancer )
Date: 2024-03-07 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Bone Cancer )
Date: 2023-05-22 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Bone Cancer )
Date: 2022-08-23 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Bone Cancer )
Date: 2022-05-02 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-21 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-12 Transparency Panel Disclosures/Attendance
Date: 2020-06-12 Transparency Panel Disclosures/Attendance
Date: 2020-05-08 Transparency Panel Disclosures/Attendance
Version: 6.2024 ( Breast Cancer )
Date: 2024-10-31 Transparency Panel Disclosures/Attendance
Version: 5.2024
Date: 2024-10-09 Transparency Panel Disclosures/Attendance
Version: 4.2024
Date: 2024-06-21 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-03-06 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-08-31 Transparency Panel Disclosures/Attendance
Date: 2023-08-30 Transparency Panel Disclosures/Attendance
Version: 5.2023
Date: 2023-11-17 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( Breast Cancer )
Date: 2023-03-08 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Breast Cancer )
Date: 2023-01-31 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer )
Date: 2022-10-28 Transparency Panel Disclosures/Attendance
Date: 2022-08-26 Transparency Panel Disclosures/Attendance
Date: 2022-08-25 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Breast Cancecr )
Date: 2022-06-16 Transparency Panel Disclosures/Attendance
Version: 2.2022
Date: 2021-12-17 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-18 Transparency Panel Disclosures/Attendance
Date: 2021-08-12 Transparency Panel Disclosures/Attendance
Version: 8.2021
Date: 2021-08-30 Transparency Panel Disclosures/Attendance
Version: 6.2021
Date: 2021-08-12 Transparency Panel Disclosures/Attendance
Version: 5.2021
Date: 2021-06-14 Transparency Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-04-23 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-23 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-01 Transparency Panel Disclosures/Attendance
Date: 2020-08-27 Transparency Panel Disclosures/Attendance
Version: 6.2020
Date: 2020-08-27 Transparency Panel Disclosures/Attendance
Version: 5.2020
Date: 2020-07-07 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-05-04 Transparency Panel Disclosures/Attendance
Date: 2020-04-27 Transparency Panel Disclosures/Attendance
Date: 2020-04-21 Transparency Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-02-27 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-01-30 Transparency Panel Disclosures/Attendance
Breast Cancer Risk Reduction Panel
Version: 1.2025 ( Breast Cancer Risk Reduction )
Date: 2024-06-07 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Breast Cancer Risk Reduction )
Date: 2024-03-08 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Breast Cancer Risk Reduction )
Date: 2023-06-09 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer Risk Reduction )
Date: 2022-09-06 Transparency Panel Disclosures/Attendance
Date: 2022-07-26 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-14 Transparency Panel Disclosures/Attendance
Breast Cancer Screening and Diagnosis Panel
Version: 1.2024 ( Breast Cancer Screening and Diagnosis )
Date: 2023-11-03 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer Screening and Diagnosis )
Date: 2022-11-18 Transparency Panel Disclosures/Attendance
Cancer in People with HIV/Kaposi Sarcoma Panel
Version: 1.2025 ( Cancer in People with HIV )
Date: 2024-07-26 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Kaposi Sarcoma )
Date: 2024-10-02 Transparency Panel Disclosures/Attendance
Date: 2024-07-26 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Kaposi Sarcoma )
Date: 2022-08-02 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Cancer in People with HIV )
Date: 2021-09-14 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Kaposi Sarcoma )
Date: 2021-09-14 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Kaposi Sarcoma )
Date: 2020-08-31 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( AIDS-Related Kaposi Sarcoma )
Date: 2020-05-21 Transparency Panel Disclosures/Attendance
Cancer-Associated Venous Thromboembolic Disease Panel
Version: 1.2024
Date: 2023-11-14 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-20 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-04-01 Transparency Panel Disclosures/Attendance
Date: 2020-03-17 Transparency Panel Disclosures/Attendance
Central Nervous System Cancers Panel
Version: 3.2024 ( Central Nervous System Cancers )
Date: 2024-08-28 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Central Nervous System Cancers )
Date: 2024-07-02 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Central Nervous System Cancers )
Date: 2023-10-06 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Central Nervous System Cancers )
Date: 2023-02-16 Transparency Panel Disclosures/Attendance
Date: 2022-10-27 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Central Nervous System Cancers )
Date: 2022-04-19 Transparency Panel Disclosures/Attendance
Date: 2021-11-17 Transparency Panel Disclosures/Attendance
Date: 2021-10-21 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-08-27 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-04-29 Transparency Panel Disclosures/Attendance
Date: 2020-10-23 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2021-03-04 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-04-22 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-02-05 Transparency Panel Disclosures/Attendance
Cervical/Uterine Cancers Panel
Version: 4.2024 ( Cervical Cancer )
Date: 2024-09-19 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Vulvar Cancer )
Date: 2024-04-16 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Uterine Neoplasms )
Date: 2024-06-20 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Cervical Cancer )
Date: 2024-02-02 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Uterine Neoplasms )
Date: 2024-02-29 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Vulvar Cancer )
Date: 2023-09-27 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Cervical Cancer )
Date: 2023-08-23 Transparency Panel Disclosures/Attendance
Date: 2023-06-30 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Uterine Neoplasms )
Date: 2023-06-30 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Vulvar Cancer )
Date: 2023-06-30 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Uterine Neoplasms )
Date: 2023-04-07 Transparency Panel Disclosures/Attendance
Date: 2023-03-21 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Cervical Cancer )
Date: 2022-11-14 Transparency Panel Disclosures/Attendance
Date: 2022-06-28 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Uterine Neoplasms )
Date: 2022-11-14 Transparency Panel Disclosures/Attendance
Date: 2022-06-28 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Vulvar Cancer )
Date: 2022-11-14 Transparency Panel Disclosures/Attendance
Date: 2022-06-28 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Cervical Cancer )
Date: 2021-10-08 Transparency Panel Disclosures/Attendance
Date: 2021-06-11 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Gestational Trophoblastic Neoplasia )
Date: 2021-06-11 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Uterine Neoplasms )
Date: 2021-10-08 Transparency Panel Disclosures/Attendance
Date: 2021-08-14 Transparency Panel Disclosures/Attendance
Date: 2021-06-11 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Vulvar Cancer )
Date: 2021-06-11 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Uterine Neoplasms )
Date: 2021-08-14 Transparency Panel Disclosures/Attendance
Date: 2021-06-11 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Uterine Neoplasms )
Date: 2021-04-27 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Cervical Cancer )
Date: 2020-06-12 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Uterine Neoplasms )
Date: 2020-09-02 Transparency Panel Disclosures/Attendance
Date: 2020-06-12 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Vulvar Cancer )
Date: 2020-09-02 Transparency Panel Disclosures/Attendance
Date: 2020-06-12 Transparency Panel Disclosures/Attendance
Version: 3.2020 ( Gestational Trophoblastic Neoplasia )
Date: 2020-09-02 Transparency Panel Disclosures/Attendance
Version: 3.2020 ( Vulvar Cancer )
Date: 2020-07-07 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Cervical Cancer )
Date: 2020-07-07 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Gestational Trophoblastic Neoplasia )
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Uterine Neoplasms )
Date: 2020-07-07 Transparency Panel Disclosures/Attendance
Chronic Myeloid Leukemia Panel
Version: 2.2025
Date: 2024-11-04 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Chronic Myeloid Leukemia )
Date: 2024-05-07 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-05-23 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-05-17 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Chronic Myeloid Leukemia )
Date: 2021-11-03 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-01-05 Transparency Panel Disclosures/Attendance
CLL/SLL/Hairy Cell Leukemia Panel
Version: 1.2025 ( CLL/SLL )
Date: 2024-07-08 Transparency Panel Disclosures/Attendance
Date: 2024-06-07 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Hairy Cell Leukemia )
Date: 2024-06-07 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( CLL/SLL )
Date: 2024-03-18 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( CLL/SLL )
Date: 2023-09-13 Transparency Panel Disclosures/Attendance
Date: 2023-06-19 Transparency Panel Disclosures/Attendance
Date: 2023-06-01 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Hairy Cell Leukemia )
Date: 2023-06-19 Transparency Panel Disclosures/Attendance
Date: 2023-06-01 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( CLL/SLL )
Date: 2023-06-01 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2022-12-22 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2022-08-08 Transparency Panel Disclosures/Attendance
Date: 2022-07-11 Transparency Panel Disclosures/Attendance
Date: 2022-06-17 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Hairy Cell Leukemia )
Date: 2022-07-11 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Chronic LymphoChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cytic Leukemia/ Small Lymphocy )
Date: 2022-01-14 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2022-01-25 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2021-07-14 Transparency Panel Disclosures/Attendance
Date: 2021-06-04 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Hairy Cell Leukemia )
Date: 2021-06-04 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-11-02 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-06-30 Transparency Panel Disclosures/Attendance
Date: 2020-06-05 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Hairy Cell Leukemia )
Date: 2020-06-30 Transparency Panel Disclosures/Attendance
Date: 2020-06-05 Transparency Panel Disclosures/Attendance
Version: 4.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-01-17 Transparency Panel Disclosures/Attendance
Colon/Rectal/Anal Cancers Panel
Version: 1.2025 ( Small Bowel Adenocarcinoma )
Date: 2024-08-29 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Anal Carcinoma )
Date: 2024-09-24 Transparency Panel Disclosures/Attendance
Date: 2024-08-29 Transparency Panel Disclosures/Attendance
Version: 5.2024 ( Colon Cancer )
Date: 2024-08-22 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Colon Cancer )
Date: 2024-06-21 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Rectal Cancer )
Date: 2024-08-22 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Small Bowel Adenocarcinoma )
Date: 2024-06-21 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Rectal Cancer )
Date: 2024-06-21 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Small Bowel Adenocarcinoma )
Date: 2024-04-17 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Colon/Rectal Cancers )
Date: 2024-04-17 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Small Bowel Adenocarcinoma )
Date: 2024-02-09 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Anal Carcinoma )
Date: 2023-08-29 Transparency Panel Disclosures/Attendance
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Colon/Rectal Cancers )
Date: 2023-08-29 Transparency Panel Disclosures/Attendance
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Small Bowel Adenocarcinoma )
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Version: 6.2023 ( Rectal Cancer )
Date: 2023-11-13 Transparency Panel Disclosures/Attendance
Version: 5.2023 ( Rectal Cancer )
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( Colon Cancer )
Date: 2023-11-13 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( Rectal Cancer )
Date: 2023-06-29 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Colon Cancer )
Date: 2023-08-28 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Rectal Cancer )
Date: 2023-04-14 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Anal Carcinoma )
Date: 2022-08-31 Transparency Panel Disclosures/Attendance
Date: 2022-08-30 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Colon/Rectal Cancers )
Date: 2023-03-06 Transparency Panel Disclosures/Attendance
Date: 2022-08-31 Transparency Panel Disclosures/Attendance
Date: 2022-08-30 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Small Bowel Adenocarcinoma )
Date: 2022-08-31 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Rectal Cancer )
Date: 2022-08-31 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Colon Cancer )
Date: 2022-08-31 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Rectal Cancer )
Date: 2022-10-17 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Colon Cancer )
Date: 2022-10-17 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Small Bowel Adenocarcinoma )
Date: 2022-10-17 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Anal Carcinoma )
Date: 2021-09-09 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Colon/Rectal Cancers )
Date: 2021-08-02 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Small Bowel Adenocarcinoma )
Date: 2021-09-09 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Colon Cancer )
Date: 2021-08-24 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Rectal Cancer )
Date: 2021-08-24 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Small Bowel Adenocarcinoma )
Date: 2021-08-24 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Anal Carcinoma )
Date: 2021-02-02 Transparency Panel Disclosures/Attendance
Date: 2020-09-29 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Colon/Rectal Cancers )
Date: 2020-09-29 Transparency Panel Disclosures/Attendance
Date: 2020-08-11 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Small Bowel Adenocarcinoma )
Date: 2021-02-02 Transparency Panel Disclosures/Attendance
Date: 2020-09-29 Transparency Panel Disclosures/Attendance
Version: 5.2020 ( Rectal Cancer )
Date: 2020-06-04 Transparency Panel Disclosures/Attendance
Version: 4.2020 ( Colon Cancer )
Date: 2020-06-04 Transparency Panel Disclosures/Attendance
Version: 3.2020 ( Colon/Rectal Cancers )
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Anal Carcinoma )
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Colon/Rectal Cancers )
Date: 2020-02-04 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Small Bowel Adenocarcinoma )
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Colorectal Cancer Screening Panel
Version: 1.2024
Date: 2023-11-08 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-03 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-05 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Distress Management )
Date: 2024-07-08 Transparency Panel Disclosures/Attendance
Esophageal/Gastric Cancers Panel
Version: 4.2024 ( Esophageal )
Date: 2024-07-12 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Gastric )
Date: 2024-07-12 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Esophageal and Esophagogastric Junction Cancers )
Date: 2024-04-03 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Esophageal )
Date: 2023-08-30 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Gastric )
Date: 2023-08-30 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( Esophageal )
Date: 2023-12-22 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Esophageal )
Date: 2023-08-07 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Gastric Cancer )
Date: 2023-12-22 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Gastric )
Date: 2023-08-07 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Esophageal )
Date: 2023-01-27 Transparency Panel Disclosures/Attendance
Date: 2022-08-30 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Gastric )
Date: 2023-01-27 Transparency Panel Disclosures/Attendance
Date: 2022-08-30 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Esophageal )
Date: 2022-08-17 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Esophageal )
Date: 2022-06-13 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Gastric )
Date: 2022-06-13 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Esophageal )
Date: 2021-12-01 Transparency Panel Disclosures/Attendance
Date: 2021-09-08 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Gastric )
Date: 2021-09-08 Transparency Panel Disclosures/Attendance
Version: 5.2021 ( Gastric Cancer )
Date: 2021-09-08 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Esophageal and Esophagogastric Cancer )
Date: 2021-07-13 Transparency Panel Disclosures/Attendance
Date: 2021-06-24 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Gastric Cancer )
Date: 2021-07-13 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Esophageal Cancer )
Date: 2021-04-28 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Gastric Cancer )
Date: 2021-04-28 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Esophageal Cancer )
Date: 2021-02-11 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Gastric Cancer )
Date: 2021-02-11 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Esophageal Cancer )
Date: 2020-12-24 Transparency Panel Disclosures/Attendance
Date: 2020-09-16 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Gastric Cancer )
Date: 2020-12-24 Transparency Panel Disclosures/Attendance
Date: 2020-09-16 Transparency Panel Disclosures/Attendance
Version: 5.2020 ( Esophageal Cancer )
Date: 2020-12-11 Transparency Panel Disclosures/Attendance
Version: 4.2020 ( Gastric Cancer )
Date: 2020-12-11 Transparency Panel Disclosures/Attendance
Version: 3.2020 ( Esophageal Cancer )
Date: 2020-06-16 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Esophageal and Esophagogastric Junction Cancers )
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Gastric Cancer )
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Version: 1.2020 ( Esophageal Cancer )
Date: 2020-01-22 Transparency Panel Disclosures/Attendance
Version: 1.2020 ( Gastric Cancer )
Date: 2020-01-22 Transparency Panel Disclosures/Attendance
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel
Version: 2.2025 ( Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate )
Date: 2024-10-29 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic )
Date: 2024-06-18 Transparency Panel Disclosures/Attendance
Date: 2024-04-29 Transparency Panel Disclosures/Attendance
Date: 2024-04-24 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-04-11 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic )
Date: 2022-04-29 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-04-09 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-22 Transparency Panel Disclosures/Attendance
Date: 2020-04-28 Transparency Panel Disclosures/Attendance
Date: 2020-04-21 Transparency Panel Disclosures/Attendance
Genetic/Familial High-Risk Assessment: Colorectal Panel
Version: 1.2024 ( Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric )
Date: 2024-01-29 Transparency Panel Disclosures/Attendance
Date: 2023-12-12 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Genetic/Familial High-Risk Assessment: Colorectal Panel )
Date: 2022-12-06 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Genetics/Familial High-Risk Assessment: Colorectal )
Date: 2021-12-13 Transparency Panel Disclosures/Attendance
Date: 2021-12-07 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-02-02 Transparency Panel Disclosures/Attendance
Date: 2020-12-14 Transparency Panel Disclosures/Attendance
Version: 1.2020 ( Genetics/Familial High-Risk Assessment: Colorectal )
Date: 2020-03-03 Transparency Panel Disclosures/Attendance
Version: 1.2025
Date: 2024-09-27 Transparency Panel Disclosures/Attendance
Date: 2024-06-04 Transparency Panel Disclosures/Attendance
Date: 2024-04-26 Transparency Panel Disclosures/Attendance
Version: 5.2024
Date: 2024-09-28 Transparency Panel Disclosures/Attendance
Version: 4.2024
Date: 2024-04-15 Transparency Panel Disclosures/Attendance
Version: 3.2024
Date: 2024-02-13 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2023-11-06 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-08-25 Transparency Panel Disclosures/Attendance
Date: 2023-05-26 Transparency Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-04-26 Transparency Panel Disclosures/Attendance
Date: 2023-02-28 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-10-03 Transparency Panel Disclosures/Attendance
Date: 2022-06-30 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-15 Transparency Panel Disclosures/Attendance
Date: 2021-06-21 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-13 Transparency Panel Disclosures/Attendance
Date: 2020-09-03 Transparency Panel Disclosures/Attendance
Date: 2020-06-25 Transparency Panel Disclosures/Attendance
Hematopoietic Cell Transplantation Panel
Version: 2.2024 ( Hematopoietic Cell Transplantation )
Date: 2024-08-19 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Hematopoietic Cell Transplantation )
Date: 2023-11-07 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Hematopoietic Cell Transplantation )
Date: 2023-10-03 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Hematopoietic Cell Transplantation )
Date: 2023-09-12 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Hematopoietic Cell Transplantation )
Date: 2022-11-04 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Hematopoietic Cell Transplantation )
Date: 2022-09-14 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-16 Transparency Panel Disclosures/Attendance
Version: 5.2021
Date: 2021-09-24 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-08-25 Transparency Panel Disclosures/Attendance
Date: 2021-07-20 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-17 Transparency Panel Disclosures/Attendance
Date: 2020-11-16 Transparency Panel Disclosures/Attendance
Date: 2020-11-13 Transparency Panel Disclosures/Attendance
Hematopoietic Growth Factors Panel
Version: 1.2025 ( Hematopoietic Growth Factors )
Date: 2024-07-18 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Hematopoietic Growth Factors )
Date: 2023-11-29 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Hematopoietic Growth Factors )
Date: 2023-08-14 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Hematopoietic Growth Factors )
Date: 2023-02-24 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-10-21 Transparency Panel Disclosures/Attendance
Date: 2022-08-31 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-18 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-04-26 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-18 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-14 Transparency Panel Disclosures/Attendance
Version: 5.2024 ( Biliary Tract Cancers )
Date: 2024-10-10 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Biliary Tract Cancers )
Date: 2024-05-16 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Hepatocellular Carcinoma )
Date: 2024-09-19 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Biliary Tract Cancers )
Date: 2024-04-09 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Hepatocellular Carcinoma )
Date: 2024-06-19 Transparency Panel Disclosures/Attendance
Date: 2024-05-16 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Biliary Tract Cancers )
Date: 2024-03-07 Transparency Panel Disclosures/Attendance
Date: 2023-10-19 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Hepatocellular Carcinoma )
Date: 2023-10-19 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Biliary Tract Cancers )
Date: 2023-10-19 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Biliary Tract Cancers )
Date: 2023-02-17 Transparency Panel Disclosures/Attendance
Date: 2022-11-17 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Hepatocellular Carcinoma )
Date: 2023-02-17 Transparency Panel Disclosures/Attendance
Date: 2022-11-17 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Hepatobiliary Cancers )
Date: 2022-11-17 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Hepatobiliary Cancers )
Date: 2022-10-05 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Hepatobiliary Cancers )
Date: 2022-07-01 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Hepatobiliary Cancers )
Date: 2022-03-11 Transparency Panel Disclosures/Attendance
Date: 2022-02-24 Transparency Panel Disclosures/Attendance
Date: 2022-02-09 Transparency Panel Disclosures/Attendance
Date: 2021-10-07 Transparency Panel Disclosures/Attendance
Version: 5.2021 ( Hepatobiliary Cancers )
Date: 2021-09-01 Transparency Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-08-13 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-06-03 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-01-20 Transparency Panel Disclosures/Attendance
Date: 2020-12-10 Transparency Panel Disclosures/Attendance
Date: 2020-10-29 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-06-09 Transparency Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-05-15 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-04-20 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-03-16 Transparency Panel Disclosures/Attendance
Date: 2020-01-31 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-06-28 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Histiocytic Neoplasms )
Date: 2022-12-02 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Histiocytic Neoplasms )
Date: 2021-12-16 Transparency Panel Disclosures/Attendance
Version: 4.2024
Date: 2024-05-10 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2023-12-07 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-04-14 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-29 Transparency Panel Disclosures/Attendance
Date: 2022-04-27 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-30 Transparency Panel Disclosures/Attendance
Date: 2021-08-19 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-30 Transparency Panel Disclosures/Attendance
Date: 2020-08-18 Transparency Panel Disclosures/Attendance
Version: 2.2025
Date: 2024-08-16 Transparency Panel Disclosures/Attendance
Version: 1.2025
Date: 2024-06-10 Transparency Panel Disclosures/Attendance
Date: 2024-04-26 Transparency Panel Disclosures/Attendance
Version: 3.2024
Date: 2024-03-07 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2023-12-18 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-06-01 Transparency Panel Disclosures/Attendance
Date: 2023-04-21 Transparency Panel Disclosures/Attendance
Version: 4.2023
Date: 2022-12-16 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Kidney Cancer )
Date: 2022-09-13 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Kidney Cancer )
Date: 2022-05-10 Transparency Panel Disclosures/Attendance
Date: 2022-04-08 Transparency Panel Disclosures/Attendance
Version: 4.2022
Date: 2021-12-10 Transparency Panel Disclosures/Attendance
Version: 2.2022
Date: 2021-08-19 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-14 Transparency Panel Disclosures/Attendance
Date: 2021-04-30 Transparency Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-03-04 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-04 Transparency Panel Disclosures/Attendance
Date: 2021-02-13 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-01-25 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-04-03 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Lung Cancer Screening )
Date: 2024-06-18 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-12 Transparency Panel Disclosures/Attendance
Management of Immunotherapy-Related Toxicity Panel
Version: 1.2024
Date: 2023-10-30 Transparency Panel Disclosures/Attendance
Date: 2023-07-13 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Management of Immunotherapy-Related Toxicities )
Date: 2023-10-03 Transparency Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-04-20 Transparency Panel Disclosures/Attendance
Date: 2023-02-01 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-15 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Management of Immunotherapy-Related Toxicities )
Date: 2022-02-15 Transparency Panel Disclosures/Attendance
Date: 2022-02-03 Transparency Panel Disclosures/Attendance
Date: 2021-12-09 Transparency Panel Disclosures/Attendance
Date: 2021-07-16 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Management of Immunotherapy-Related Toxicities )
Date: 2021-09-23 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-03-10 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-11 Transparency Panel Disclosures/Attendance
Date: 2020-07-14 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Melanoma: Cutaneous )
Date: 2024-09-19 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Melanoma: Cutaneous )
Date: 2024-03-13 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Melanoma: Cutaneous )
Date: 2023-12-15 Transparency Panel Disclosures/Attendance
Date: 2023-07-17 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Melanoma: Uveal )
Date: 2024-04-29 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Cutaneous )
Date: 2023-10-20 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Melanoma: Cutaneous )
Date: 2023-02-04 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Melanoma: Cutaneous )
Date: 2022-11-22 Transparency Panel Disclosures/Attendance
Date: 2022-07-14 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Melanoma: Uveal )
Date: 2023-03-24 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Melanoma: Cutaneous )
Date: 2022-03-23 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Melanoma: Cutaneous )
Date: 2021-12-23 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Cutaneous Melanoma )
Date: 2021-10-10 Transparency Panel Disclosures/Attendance
Date: 2021-07-19 Transparency Panel Disclosures/Attendance
Date: 2021-07-12 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Melanoma: Uveal )
Date: 2022-03-07 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Cutaneous Melanoma )
Date: 2021-01-29 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-12 Transparency Panel Disclosures/Attendance
Date: 2020-07-13 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-08-05 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Uveal Melanoma )
Date: 2020-09-03 Transparency Panel Disclosures/Attendance
Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel
Version: 2.2025 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2024-12-06 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Amyloidosis )
Date: 2024-04-17 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Myeloma )
Date: 2024-04-17 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Waldenstrom )
Date: 2024-04-17 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Multiple Myeloma )
Date: 2024-04-09 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Multiple Myeloma )
Date: 2024-03-04 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Multiple Myeloma )
Date: 2023-04-18 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( Multiple Myeloma )
Date: 2023-08-15 Transparency Panel Disclosures/Attendance
Date: 2023-08-10 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Multiple Myeloma )
Date: 2022-11-23 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Multiple Myeloma )
Date: 2022-10-26 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Multiple Myeloma )
Date: 2022-04-28 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Systemic Light Chain Amyloidosis )
Date: 2022-04-28 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Waldenström Macroglobulinemia Panel )
Date: 2022-04-28 Transparency Panel Disclosures/Attendance
Version: 5.2022 ( Multiple Myeloma )
Date: 2022-03-02 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Multiple Myeloma )
Date: 2021-12-03 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Multiple Myeloma )
Date: 2021-10-25 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Multiple Myeloma )
Date: 2021-10-11 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2021-11-23 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Multiple Myeloma )
Date: 2021-04-16 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Systemic Light Chain Amyloidosis )
Date: 2021-04-16 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2021-04-16 Transparency Panel Disclosures/Attendance
Version: 6.2021 ( Multiple Myeloma )
Date: 2021-03-29 Transparency Panel Disclosures/Attendance
Version: 5.2021 ( Multiple Myeloma )
Date: 2021-03-01 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Multiple Myeloma )
Date: 2020-11-16 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Multiple Myeloma )
Date: 2020-09-01 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Systemic Light Chain Amyloidosis )
Date: 2021-01-28 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Multiple Myeloma )
Date: 2020-08-13 Transparency Panel Disclosures/Attendance
Date: 2020-07-22 Transparency Panel Disclosures/Attendance
Date: 2020-04-20 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Systemic Light Chain Amyloidosis )
Date: 2020-04-20 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2020-04-20 Transparency Panel Disclosures/Attendance
Version: 4.2020 ( Multiple Myeloma )
Date: 2020-05-04 Transparency Panel Disclosures/Attendance
Version: 3.2020 ( Multiple Myeloma )
Date: 2020-03-03 Transparency Panel Disclosures/Attendance
Myelodysplastic Syndromes Panel
Version: 1.2025
Date: 2024-09-26 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Myelodysplastic Syndromes )
Date: 2024-06-13 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( MDS )
Date: 2024-09-26 Transparency Panel Disclosures/Attendance
Date: 2024-07-09 Transparency Panel Disclosures/Attendance
Date: 2024-06-13 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( MDS )
Date: 2024-01-10 Transparency Panel Disclosures/Attendance
Date: 2023-07-20 Transparency Panel Disclosures/Attendance
Version: 3.2023
Date: 2023-10-31 Transparency Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-09-20 Transparency Panel Disclosures/Attendance
Date: 2023-09-20 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Myelodysplastic Syndromes )
Date: 2022-08-11 Transparency Panel Disclosures/Attendance
Date: 2022-06-02 Transparency Panel Disclosures/Attendance
Version: 2.2022
Date: 2021-11-05 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Myelodysplastic Syndromes )
Date: 2021-04-05 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-13 Transparency Panel Disclosures/Attendance
Date: 2020-04-14 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-02-27 Transparency Panel Disclosures/Attendance
Myeloproliferative Neoplasms Panel
Version: 2.2024 ( Systemic Mastocytosis )
Date: 2024-03-07 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Myeloproliferative Neoplasms )
Date: 2023-11-27 Transparency Panel Disclosures/Attendance
Date: 2023-08-23 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Systemic Mastocytosis )
Date: 2023-08-23 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Myeloproliferative Neoplasms )
Date: 2023-10-02 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Systemic Mastocytosis )
Date: 2023-06-23 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Systemic Mastocytosis )
Date: 2023-05-25 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions )
Date: 2023-04-25 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Myeloproliferative Neoplasms )
Date: 2023-04-25 Transparency Panel Disclosures/Attendance
Date: 2022-08-22 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2022-10-10 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Myeloproliferative Neoplasmsl )
Date: 2022-03-10 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2021-12-21 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Myeloproliferative Neoplasms )
Date: 2021-12-07 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Systemic Mastocytosis )
Date: 2021-12-21 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2020-08-14 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Systemic Mastocytosis )
Date: 2021-06-24 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2020-07-21 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-10 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-04-14 Transparency Panel Disclosures/Attendance
Date: 2020-04-14 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-07-12 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2024-06-07 Transparency Panel Disclosures/Attendance
Date: 2024-02-28 Transparency Panel Disclosures/Attendance
Date: 2023-10-13 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Neuroendocrine and Adrenal Tumors )
Date: 2023-05-25 Transparency Panel Disclosures/Attendance
Date: 2022-10-10 Transparency Panel Disclosures/Attendance
Version: 2.2022
Date: 2022-12-05 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2022-05-13 Transparency Panel Disclosures/Attendance
Date: 2022-03-28 Transparency Panel Disclosures/Attendance
Date: 2021-11-19 Transparency Panel Disclosures/Attendance
Date: 2021-11-08 Transparency Panel Disclosures/Attendance
Date: 2021-10-25 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Neuroendocrine and Adrenal Tumors )
Date: 2021-11-08 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-03-26 Transparency Panel Disclosures/Attendance
Date: 2021-01-22 Transparency Panel Disclosures/Attendance
Date: 2020-12-11 Transparency Panel Disclosures/Attendance
Date: 2020-11-20 Transparency Panel Disclosures/Attendance
Date: 2020-11-09 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-06-30 Transparency Panel Disclosures/Attendance
Date: 2020-06-01 Transparency Panel Disclosures/Attendance
Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel
Version: 1.2025 ( Mesothelioma: Peritoneal )
Date: 2024-07-11 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Mesothelioma: Pleural )
Date: 2024-07-11 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Non-Small Cell Lung Cancer )
Date: 2024-12-10 Transparency Panel Disclosures/Attendance
Date: 2024-07-12 Transparency Panel Disclosures/Attendance
Date: 2024-07-11 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Thymomas and Thymic Carcinomas )
Date: 2024-07-11 Transparency Panel Disclosures/Attendance
Version: 9.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-08-27 Transparency Panel Disclosures/Attendance
Version: 8.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-07-12 Transparency Panel Disclosures/Attendance
Version: 7.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-06-19 Transparency Panel Disclosures/Attendance
Version: 6.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-06-11 Transparency Panel Disclosures/Attendance
Version: 5.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-04-17 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Mesothelioma: Peritoneal )
Date: 2024-09-25 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-03-08 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Mesothelioma: Peritoneal )
Date: 2024-09-18 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Mesothelioma: Pleural )
Date: 2024-09-25 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-02-02 Transparency Panel Disclosures/Attendance
Version: 11.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-07-12 Transparency Panel Disclosures/Attendance
Version: 10.2024 ( Non-Small Cell Lung Cancer )
Date: 2024-09-18 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Mesothelioma: Peritoneal )
Date: 2023-11-07 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Mesothelioma: Pleural )
Date: 2023-07-10 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Non-Small Cell Lung Cancer )
Date: 2023-12-08 Transparency Panel Disclosures/Attendance
Date: 2023-07-17 Transparency Panel Disclosures/Attendance
Date: 2023-07-11 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Thymomas and Thymic Carcinomas )
Date: 2023-07-10 Transparency Panel Disclosures/Attendance
Version: 5.2023 ( Non-Small Cell Lung Cancer )
Date: 2023-10-30 Transparency Panel Disclosures/Attendance
Date: 2023-07-11 Transparency Panel Disclosures/Attendance
Version: 4.2023 ( Non-Small Cell Lung Cancer )
Date: 2023-10-15 Transparency Panel Disclosures/Attendance
Date: 2023-07-11 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Non-Small Cell Lung Cancer )
Date: 2023-02-15 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Mesothelioma: Peritoneal )
Date: 2022-07-22 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Mesothelioma: Pleural )
Date: 2022-07-22 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Non-Small Cell Lung Cancer )
Date: 2022-12-12 Transparency Panel Disclosures/Attendance
Date: 2022-07-08 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Thymomas and Thymic Carcinomas )
Date: 2022-07-22 Transparency Panel Disclosures/Attendance
Version: 6.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-11-18 Transparency Panel Disclosures/Attendance
Version: 5.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-07-08 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-08-22 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-03-09 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-07-09 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Malignant Pleural Mesothelioma )
Date: 2021-07-20 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Thymomas and Thymic Carcinomas )
Date: 2021-07-20 Transparency Panel Disclosures/Attendance
Version: 7.2021 ( Non-Small Lung Cancer )
Date: 2021-10-15 Transparency Panel Disclosures/Attendance
Version: 6.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-09-19 Transparency Panel Disclosures/Attendance
Version: 5.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-06-01 Transparency Panel Disclosures/Attendance
Version: 4.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-02-23 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-02-04 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Malignant Pleural Mesothelioma )
Date: 2021-02-04 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Non-Small Cell Lung Cancer )
Date: 2020-12-08 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Malignant Pleural Mesothelioma )
Date: 2020-09-04 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Non-Small Cell Lung Cancer )
Date: 2020-11-09 Transparency Panel Disclosures/Attendance
Date: 2020-07-27 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Thymomas and Thymic Carcinomas )
Date: 2020-09-04 Transparency Panel Disclosures/Attendance
Version: 7.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-09-08 Transparency Panel Disclosures/Attendance
Version: 6.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-06-03 Transparency Panel Disclosures/Attendance
Version: 5.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-05-20 Transparency Panel Disclosures/Attendance
Version: 4.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-05-11 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Malignant Pleural Mesothelioma )
Date: 2020-10-09 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Occult Primary )
Date: 2024-06-24 Transparency Panel Disclosures/Attendance
Date: 2024-05-10 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Occult )
Date: 2024-04-09 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Occult Primary )
Date: 2023-04-11 Transparency Panel Disclosures/Attendance
Version: 2.2023
Date: 2022-10-05 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Occult Primary )
Date: 2022-04-19 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-24 Transparency Panel Disclosures/Attendance
Date: 2021-06-07 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-10 Transparency Panel Disclosures/Attendance
Date: 2020-06-10 Transparency Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-05-01 Transparency Panel Disclosures/Attendance
Version: 1.2025 ( Older Adult Oncology )
Date: 2024-09-06 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-09-29 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Older Adult Oncology )
Date: 2021-12-03 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-22 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Ovarian Cancer )
Date: 2024-06-27 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-04-10 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Ovarian Cancer )
Date: 2023-11-02 Transparency Panel Disclosures/Attendance
Date: 2023-10-27 Transparency Panel Disclosures/Attendance
Date: 2023-10-02 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Ovarian Cancer )
Date: 2023-05-23 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Ovarian Cancer )
Date: 2022-12-08 Transparency Panel Disclosures/Attendance
Date: 2022-12-06 Transparency Panel Disclosures/Attendance
Date: 2022-10-31 Transparency Panel Disclosures/Attendance
Version: 5.2022 ( Ovarian Cancer )
Date: 2022-09-08 Transparency Panel Disclosures/Attendance
Version: 4.2022 ( Ovarian Cancer )
Date: 2022-08-16 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Ovarian Cancer )
Date: 2022-06-29 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-12-07 Transparency Panel Disclosures/Attendance
Date: 2021-10-07 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-08-31 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-18 Transparency Panel Disclosures/Attendance
Date: 2020-10-16 Transparency Panel Disclosures/Attendance
Date: 2020-10-02 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-02-10 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-07-31 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-22 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-04 Transparency Panel Disclosures/Attendance
Pancreatic Adenocarcinoma Panel
Version: 3.2024 ( Pancreatic Adenocarcinoma )
Date: 2024-06-27 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-04-11 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Ampullary Adenocarcinoma )
Date: 2024-06-27 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Ampullary Adenocarcinoma )
Date: 2023-08-18 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Pancreatic Adenocarcinoma )
Date: 2023-11-03 Transparency Panel Disclosures/Attendance
Date: 2023-09-05 Transparency Panel Disclosures/Attendance
Date: 2023-08-18 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Pancreatic Adenocarcinoma )
Date: 2023-05-23 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Ampullary Adenocarcinoma )
Date: 2023-03-10 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Pancreatic Adenocarcinoma )
Date: 2023-03-16 Transparency Panel Disclosures/Attendance
Date: 2022-08-12 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Ampullary Adenocarcinoma )
Date: 2022-10-14 Transparency Panel Disclosures/Attendance
Version: 2.2022 ( Pancreatic Adenocarcinoma )
Date: 2022-10-14 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Pancreatic Adenocarcinoma )
Date: 2022-01-24 Transparency Panel Disclosures/Attendance
Date: 2021-08-31 Transparency Panel Disclosures/Attendance
Date: 2021-07-29 Transparency Panel Disclosures/Attendance
Date: 2021-07-08 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-07-23 Transparency Panel Disclosures/Attendance
Date: 2020-07-09 Transparency Panel Disclosures/Attendance
Pediatric Acute Lymphoblastic Leukemia Panel
Version: 2.2025 ( Pediatric Acute Lymphoblastic Leukemia )
Date: 2024-11-22 Transparency Panel Disclosures/Attendance
Version: 1.2025
Date: 2024-06-07 Transparency Panel Disclosures/Attendance
Date: 2024-05-22 Transparency Panel Disclosures/Attendance
Version: 6.2024
Date: 2024-07-10 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Pediatric Acute Lymphoblastic Leukemia )
Date: 2023-10-10 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-06-28 Transparency Panel Disclosures/Attendance
Date: 2023-05-24 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-05-25 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-09 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-07-13 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-12 Transparency Panel Disclosures/Attendance
Pediatric Aggressive Mature B-Cell Lymphomas Panel
Version: 1.2023
Date: 2022-12-06 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-01 Transparency Panel Disclosures/Attendance
Pediatric Central Nervous System Cancers Panel
Version: 1.2025
Date: 2024-08-27 Transparency Panel Disclosures/Attendance
Pediatric Hodgkin Lymphoma Panel
Version: 1.2024
Date: 2024-04-15 Transparency Panel Disclosures/Attendance
Date: 2023-11-15 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-12-14 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2022-02-08 Transparency Panel Disclosures/Attendance
Date: 2021-09-10 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2020-10-16 Transparency Panel Disclosures/Attendance
Prevention and Treatment of Cancer-Related Infections Panel
Version: 1.2023
Date: 2022-12-05 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-12-08 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-20 Transparency Panel Disclosures/Attendance
Prostate Cancer Early Detection Panel
Version: 1.2024
Date: 2023-09-29 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-12-15 Transparency Panel Disclosures/Attendance
Date: 2022-09-12 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Prostate Cancer Early Detection )
Date: 2021-11-04 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-19 Transparency Panel Disclosures/Attendance
Version: 1.2025
Date: 2024-10-16 Transparency Panel Disclosures/Attendance
Date: 2024-10-09 Transparency Panel Disclosures/Attendance
Date: 2024-05-17 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Prostate Cancer )
Date: 2024-03-04 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Prostate Cancer )
Date: 2024-01-29 Transparency Panel Disclosures/Attendance
Date: 2023-09-28 Transparency Panel Disclosures/Attendance
Date: 2023-05-19 Transparency Panel Disclosures/Attendance
Version: 4.2023
Date: 2023-08-30 Transparency Panel Disclosures/Attendance
Date: 2023-08-25 Transparency Panel Disclosures/Attendance
Date: 2023-08-16 Transparency Panel Disclosures/Attendance
Version: 3.2023
Date: 2023-07-21 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Prostate )
Date: 2023-06-12 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-08-09 Transparency Panel Disclosures/Attendance
Date: 2022-07-18 Transparency Panel Disclosures/Attendance
Date: 2022-05-02 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Prostate Cancer )
Date: 2022-08-19 Transparency Panel Disclosures/Attendance
Version: 4.2022
Date: 2022-05-02 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-20 Transparency Panel Disclosures/Attendance
Date: 2021-06-28 Transparency Panel Disclosures/Attendance
Date: 2021-05-07 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-05 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-14 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-05-19 Transparency Panel Disclosures/Attendance
Date: 2020-05-14 Transparency Panel Disclosures/Attendance
Skin Cancers Excluding Melanoma Panel
Version: 1.2024 ( Basal Cell Skin Cancer )
Date: 2023-08-18 Transparency Panel Disclosures/Attendance
Date: 2023-05-01 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Merkel Cell Carcinoma )
Date: 2023-10-27 Transparency Panel Disclosures/Attendance
Date: 2023-10-03 Transparency Panel Disclosures/Attendance
Date: 2023-06-26 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Squamous Cell Skin Cancer )
Date: 2023-10-03 Transparency Panel Disclosures/Attendance
Date: 2023-05-15 Transparency Panel Disclosures/Attendance
Date: 2023-05-01 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Basal Cell Skin Cancer )
Date: 2023-01-11 Transparency Panel Disclosures/Attendance
Date: 2022-05-16 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Merkel Cell Carcinoma )
Date: 2023-03-24 Transparency Panel Disclosures/Attendance
Date: 2023-03-10 Transparency Panel Disclosures/Attendance
Date: 2022-05-16 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Squamous Cell Skin Cancer )
Date: 2023-02-08 Transparency Panel Disclosures/Attendance
Date: 2022-05-16 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Basal Cell Skin Cancer and Squamous Cell Skin Cancer )
Date: 2021-10-05 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Merkel Cell Carcinoma )
Date: 2021-05-21 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Basal Cell Skin Cancer )
Date: 2021-02-18 Transparency Panel Disclosures/Attendance
Version: 2.2021 ( Squamous Cell Skin Cancer )
Date: 2021-08-02 Transparency Panel Disclosures/Attendance
Date: 2021-07-20 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Basal Cell Skin Cancer, Merkel Cell Carcinoma, Squamous Cell Skin Cancer )
Date: 2020-06-18 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Squamous Cell Skin Cancer )
Date: 2021-01-14 Transparency Panel Disclosures/Attendance
Version: 2.2020 ( Squamous Cell Skin Cancer )
Date: 2020-07-01 Transparency Panel Disclosures/Attendance
Version: 3.2025 ( Small Cell Lung Cancer )
Date: 2024-10-10 Transparency Panel Disclosures/Attendance
Version: 1.2025
Date: 2024-04-25 Transparency Panel Disclosures/Attendance
Version: 3.2024
Date: 2024-05-29 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-04-20 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Small Cell Lung Cancer )
Date: 2022-04-21 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-04-21 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-12 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-02 Transparency Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-01-05 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-04 Transparency Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-06-17 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-12-16 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-04 Transparency Panel Disclosures/Attendance
Version: 4.2024 ( Soft Tissue Sarcoma )
Date: 2024-09-18 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Soft Tissue Sarcoma )
Date: 2024-09-18 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Gastrointestinal Stromal Tumors )
Date: 2024-06-26 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( Soft Tissue Sarcoma )
Date: 2024-06-26 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Gastrointestinal Stromal Tumors )
Date: 2023-09-27 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Soft Tissue Sarcoma )
Date: 2024-02-07 Transparency Panel Disclosures/Attendance
Date: 2023-09-27 Transparency Panel Disclosures/Attendance
Version: 3.2023 ( Soft Tissue Sarcoma )
Date: 2023-11-29 Transparency Panel Disclosures/Attendance
Version: 2.2023 ( Soft Tissue Sarcoma )
Date: 2023-04-12 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Gastrointestinal Stromal Tumors )
Date: 2023-02-03 Transparency Panel Disclosures/Attendance
Date: 2022-09-13 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Soft Tissue Sarcoma )
Date: 2023-03-09 Transparency Panel Disclosures/Attendance
Date: 2023-02-03 Transparency Panel Disclosures/Attendance
Date: 2022-09-13 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Gastrointestinal Stromal Tumors (GISTs) )
Date: 2021-07-09 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Soft Tissue Sarcoma )
Date: 2022-02-16 Transparency Panel Disclosures/Attendance
Date: 2021-10-19 Transparency Panel Disclosures/Attendance
Date: 2021-06-11 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Soft Tissue Sarcoma )
Date: 2022-01-12 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Gastrointestinal Stromal Tumors (GISTs) )
Date: 2020-07-08 Transparency Panel Disclosures/Attendance
Date: 2020-07-07 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Soft Tissue Sarcoma )
Date: 2020-08-25 Transparency Panel Disclosures/Attendance
Date: 2020-07-08 Transparency Panel Disclosures/Attendance
Date: 2020-07-07 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-05-18 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-05-05 Transparency Panel Disclosures/Attendance
Version: 6.2019
Date: 2020-01-31 Transparency Panel Disclosures/Attendance
Version: 5.2019
Date: 2020-01-14 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Survivorship )
Date: 2023-10-17 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Survivorship )
Date: 2023-02-02 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Survivorship )
Date: 2021-10-04 Transparency Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-04 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-01-31 Transparency Panel Disclosures/Attendance
T-Cell/Primary Cutaneous Lymphomas Panel
Version: 1.2025 ( T-cell Lymphomas )
Date: 2024-07-31 Transparency Panel Disclosures/Attendance
Version: 3.2024 ( Primary Cutaneous Lymphomas )
Date: 2024-07-31 Transparency Panel Disclosures/Attendance
Version: 2.2024 ( T-Cell Lymphomas )
Date: 2024-02-21 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( Primary Cutaneous Lymphomas )
Date: 2023-08-15 Transparency Panel Disclosures/Attendance
Version: 1.2024 ( T-Cell Lymphomas )
Date: 2023-08-15 Transparency Panel Disclosures/Attendance
Date: 2023-07-19 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( T-Cell Lymphomas )
Date: 2022-10-31 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( Primary Cutaneous Lymphomas )
Date: 2022-10-31 Transparency Panel Disclosures/Attendance
Date: 2022-07-08 Transparency Panel Disclosures/Attendance
Version: 1.2023 ( T-Cell Lymphomas )
Date: 2022-12-15 Transparency Panel Disclosures/Attendance
Date: 2022-07-08 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( Primary Cutaneous Lymphomas )
Date: 2021-12-03 Transparency Panel Disclosures/Attendance
Version: 1.2022 ( T-Cell Lymphomas )
Date: 2021-12-17 Transparency Panel Disclosures/Attendance
Date: 2021-07-19 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( Primary Cutaneous Lymphomas )
Date: 2020-07-10 Transparency Panel Disclosures/Attendance
Version: 1.2021 ( T-Cell Lymphomas )
Date: 2020-07-10 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-08-01 Transparency Panel Disclosures/Attendance
Date: 2023-06-23 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-06-17 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-18 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-19 Transparency Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-05-06 Transparency Panel Disclosures/Attendance
Version: 4.2024
Date: 2024-07-18 Transparency Panel Disclosures/Attendance
Version: 3.2024
Date: 2024-06-18 Transparency Panel Disclosures/Attendance
Version: 2.2024
Date: 2024-03-12 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-11-16 Transparency Panel Disclosures/Attendance
Date: 2023-09-08 Transparency Panel Disclosures/Attendance
Version: 3.2023
Date: 2022-08-15 Transparency Panel Disclosures/Attendance
Version: 2.2023
Date: 2022-08-15 Transparency Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-08-15 Transparency Panel Disclosures/Attendance
Date: 2022-08-15 Transparency Panel Disclosures/Attendance
Version: 3.2022 ( Thyroid Carcinoma )
Date: 2022-04-22 Transparency Panel Disclosures/Attendance
Version: 2.2022
Date: 2022-04-22 Transparency Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-27 Transparency Panel Disclosures/Attendance
Date: 2021-10-27 Transparency Panel Disclosures/Attendance
Version: 3.2021 ( Thyroid Carcinoma )
Date: 2021-10-15 Transparency Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-04-15 Transparency Panel Disclosures/Attendance
Date: 2020-10-07 Transparency Panel Disclosures/Attendance
Date: 2020-10-02 Transparency Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-12-21 Transparency Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-06-25 Transparency Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-06-05 Transparency Panel Disclosures/Attendance
Date: 2020-05-26 Transparency Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-10-23 Transparency Panel Disclosures/Attendance
No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.
See Legal Notices Section for additional notices and terms governing your use of this Site.